VivoSeq
Other

Phase 2

0

Pipeline Programs↗

23

Active Trials↗

59

Companies Involved↗

Phase 2 is an early-stage landscape with 0 programs across 59 companies. The most active players are Pfizer, Portola Pharmaceuticals, Kyowa Kirin Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalP

Portola Pharmaceuticals

0 programs

PreclinicalKyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalA

Abbisko Therapeutics Co, Ltd

0 programs

PreclinicalOtsuka logo

Otsuka

0 programs

PreclinicalL

La Jolla Pharmaceutical Company

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

127

clinical trials

Completed77 · 61%
Terminated15 · 12%
Recruiting11 · 9%
Active, not recruiting7 · 6%
Unknown status6 · 5%
Withdrawn6 · 5%
Other5 · 4%

Clinical Trials

Trial Activity

127 trials

A Phase 2 Clinical Study of ABSK061 and ABSK043
Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT06632262·202 enrolled
SB17170 Phase 2 Trial in IPF Patients
Recruiting·SSPARK Biopharma·Phase 2·NCT06747923·30 enrolled
Multi-modal Imaging of Myofascial Pain - Phase 2
Recruiting·WWashington University School of Medicine·N/A·NCT07322445·100 enrolled
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 2·NCT04775706·18 enrolled
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Recruiting·Vertex Pharmaceuticals logoVertex Pharmaceuticals·Phase 2·NCT07161037·24 enrolled
A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
Recruiting·GGilgamesh Pharmaceuticals·Phase 2·NCT06236880·124 enrolled
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Recruiting·RReCode Therapeutics·Phase 2·NCT06237335·192 enrolled
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Recruiting·PPharmaEssentia Japan K.K.·Phase 3·NCT04655092·67 enrolled
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
Recruiting·WWestVac Biopharma Co., Ltd.·Phase 2·NCT07170800·60 enrolled
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Recruiting·Novartis logoNovartis·Phase 2·NCT06868290·126 enrolled
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Recruiting·HHangzhou Hanx Biopharmaceuticals, Ltd.·Phase 1/2·NCT06703255·72 enrolled
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
Active, not recruiting·NNoah Pharmaceuticals, Inc.·Phase 2·NCT06597058·103 enrolled
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Active, not recruiting·NNuvation Bio Inc.·Phase 2·NCT04919811·217 enrolled
Phase 2b Controlled Study
Active, not recruiting·IIVIEW Therapeutics Inc.·Phase 2·NCT07140380·30 enrolled
Phase 2b Controlled Study of Dosing Techniques - Part B
Active, not recruiting·IIVIEW Therapeutics Inc.·Phase 2·NCT07161011·30 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)